Neon Therapeutics Congratulates Founder James P. Allison, Ph.D., for 2018 Nobel Prize in Physiology or Medicine
October 01, 2018 09:47 ET
|
Neon Therapeutics, Inc.
Award Recognizes Achievements in Cancer Immunotherapy CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing...
Neon Therapeutics to Present at Upcoming Investor Conferences in October
September 25, 2018 16:15 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
Neon Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
September 06, 2018 16:15 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
Neon Therapeutics Appoints Jolie M. Siegel as General Counsel
August 21, 2018 16:15 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...
Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights
August 06, 2018 16:15 ET
|
Neon Therapeutics, Inc.
– Successfully completed initial public offering, raising $100 million in gross proceeds – – Significant progress across platform and portfolio of vaccine and T-cell programs – – Enrollment...
Neon Therapeutics Announces Closing of Initial Public Offering
June 29, 2018 16:15 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...
Neon Therapeutics Announces Pricing of Initial Public Offering
June 26, 2018 18:56 ET
|
Neon Therapeutics, Inc.
CAMBRIDGE, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...